WGS (GeneDx Holdings) Current Accrued Expense: $30.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
65 GF Score
Price $90.88
GF Value $73.77
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GeneDx Holdings Current Accrued Expense?

GeneDx Holdings WGS +0.62% 65 Current Accrued Expense is $30.2 Mil as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GeneDx Holdings's Current Accrued Expense for the quarter that ended in Jun. 2026 was $30.2 Mil.

GeneDx Holdings's quarterly Current Accrued Expense declined from Dec. 2025 ($44.7 Mil) to Mar. 2026 ($24.7 Mil) but then increased from Mar. 2026 ($24.7 Mil) to Jun. 2026 ($30.2 Mil).

GeneDx Holdings's annual Current Accrued Expense increased from Dec. 2023 ($12.2 Mil) to Dec. 2024 ($12.4 Mil) and increased from Dec. 2024 ($12.4 Mil) to Dec. 2025 ($44.7 Mil).

GeneDx Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for GeneDx Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneDx Holdings Current Accrued Expense Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 31.00 28.95 12.18 12.44 44.66

GeneDx Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.12 26.37 44.66 24.66 30.20
WGS
65GF Score
GeneDx Holdings Corp WGS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneDx Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $30.2 Mil mean?
GeneDx Holdings (WGS) has a Current Accrued Expense of $30.2 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on GeneDx Holdings and its competitors.
Is GeneDx Holdings' Current Accrued Expense too high?
GeneDx Holdings' current Current Accrued Expense is $30.2 Mil. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Current Accrued Expense compare to NEO and CDNA?
GeneDx Holdings' Current Accrued Expense of $30.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on GeneDx Holdings and its competitors. GeneDx Holdings's current Current Accrued Expense is $30.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.88 — trading 23.2% above its estimated fair value. The current Current Accrued Expense is $30.2 Mil. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Current Accrued Expense is $30.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $90.88 is trading 23.2% above its estimated GF Value™ of $73.77. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Current Accrued Expense: $30.2 Mil
  • GF Value™: $73.77 vs. price of $90.88 (23.2% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score

Get the complete analysis for WGS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.88
Price
$73.77
GF Value